Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18)
Document Type
- Journal article (17)
- Preprint (1)
Language
- English (18)
Keywords
- CXCR4 (5)
- PRRT (5)
- multiple myeloma (5)
- PET (4)
- PET/CT (3)
- medicine (3)
- molecular imaging (3)
- neuroendocrine tumor (3)
- positron emission tomography (3)
- theranostics (3)
- FDG (2)
- MAG3 (2)
- NET (2)
- Positronen-Emissions-Tomografie (2)
- RADS (2)
- SSTR (2)
- SSTR-RADS (2)
- bone disease (2)
- chemokine receptor (2)
- peptide receptor radionuclide therapy (2)
- 177Lu (1)
- 18FDG-PET/CT (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATOC (1)
- Arginine (1)
- CXCR4/SDF-1 (1)
- DOTATOC (1)
- FDG PET/CT (1)
- FDG-PET/CT (1)
- Hyperkalaemia (1)
- Lysine (1)
- MI-RADS (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- Multiple myeloma (1)
- PROMISE (1)
- PSMA (1)
- PSMA-RADS (1)
- Positron emission tomography (1)
- SPECT (1)
- Somatostatin receptor expression (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{68}\)Ga-Pentixafor (1)
- amino acids (1)
- autologous transplantation (1)
- cancer (1)
- cardiac neurohormonal system (1)
- cells (1)
- chemokine receptor-4 (1)
- endocrinology (1)
- esophagogastric junction (1)
- experience (1)
- glioblastoma (1)
- glioblastoma multiforme (1)
- glioma (1)
- heart failure (1)
- hyperkalemia (1)
- imaging (1)
- imaging techniques (1)
- immunostaining (1)
- in vivo imaging (1)
- involvement (1)
- kidney function (1)
- macrophages (1)
- magnetic resonance imaging (1)
- malignancies (1)
- management (1)
- microenvironment (1)
- microglial cells (1)
- molecular medicine (1)
- neuroendocrine neoplasia (1)
- nuclear cardiology (1)
- pleural mesothelioma (1)
- positron emission tomography/computed tomography (1)
- prostate cancer (1)
- prostate-specific membrane antigen (1)
- radionuclide therapy (1)
- radiotracer (1)
- renal scintigraphy (1)
- reporting and data system (1)
- somatostatin (1)
- somatostatin receptor (1)
- standardized reporting (1)
- stem-cell transplantation (1)
- survival (1)
- treatment response (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (17)
- Medizinische Klinik und Poliklinik II (7)
- Pathologisches Institut (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Medizinische Klinik und Poliklinik I (2)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Medizinische Strahlenkunde und Zellforschung (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (2)
C-X-C motif chemokine receptor 4 (CXCR4) and somatostatin receptors (SSTR) are overexpressed in gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In this study, we aimed to elucidate the feasibility of non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GEP-NET patients using [\(^{68}\)Ga]Pentixafor in comparison to \(^{68}\)Ga-DOTA-D-Phe-Tyr3-octreotide ([\(^{68}\)Ga]DOTATOC) and \(^{18}\)F-fluorodeoxyglucose ([\(^{18}\)F]FDG). Twelve patients with histologically proven GEP-NET (3xG1, 4xG2, 5xG3) underwent [\(^{68}\)Ga]DOTATOC, [\(^{18}\)F]FDG, and [\(^{68}\)Ga]Pentixafor PET/CT for staging and planning of the therapeutic management. Scans were analyzed on a patient as well as on a lesion basis and compared to immunohistochemical staining patterns of CXCR4 and somatostatin receptors SSTR2a and SSTR5. [\(^{68}\)Ga]Pentixafor visualized tumor lesions in 6/12 subjects, whereas [\(^{18}\)F]FDG revealed sites of disease in 10/12 and [\(^{68}\)Ga]DOTATOC in 11/12 patients, respectively. Regarding sensitivity, SSTR-directed PET was the superior imaging modality in all G1 and G2 NET. CXCR4-directed PET was negative in all G1 NET. In contrast, 50% of G2 and 80% of G3 patients exhibited [\(^{68}\)Ga]Pentixafor-positive tumor lesions. Whereas CXCR4 seems to play only a limited role in detecting well-differentiated NET, increasing receptor expression could be non-invasively observed with increasing tumor grade. Thus, [\(^{68}\)Ga]Pentixafor PET/CT might serve as non-invasive read-out for evaluating the possibility of CXCR4-directed endoradiotherapy in advanced dedifferentiated SSTR-negative tumors.